The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications

Simple Summary The tyrosine kinase receptor Axl is an oncogene that promotes cancer development by increasing proliferation, survival, invasion, and migration in cancer cells. Axl also contributes to the development of resistance to chemo-, radio-, immune- and targeted therapy in many cancer types. It is a promising therapeutic target, and several inhibitors directed to Axl are currently in clinical trials. The understanding of Axl's role in the development of resistance can lead to improved and new cancer therapeutic strategies. Resistance to chemotherapeutic agents by cancer cells has remained a major obstacle in the successful treatment of various cancers. Numerous factors such as DNA damage repair, cell death inhibition, epithelial-mesenchymal transition, and evasion of apoptosis have all been implicated in the promotion of chemoresistance. The receptor tyrosine kinase Axl, a member of the TAM family (which includes TYRO3 and MER), plays an important role in the regulation of cellular processes such as proliferation, motility, survival, and immunologic response. The overexpression of Axl is reported in several solid and hematological malignancies, including non-small cell lung, prostate, breast, liver and gastric cancers, and acute myeloid leukaemia. The overexpression of Axl is associated with poor prognosis and the development of resistance to therapy. Reports show that Axl overexpression confers drug resistance in lung cancer and advances the emergence of tolerant cells. Axl is, therefore, an important candidate as a prognostic biomarker and target for anticancer therapies. In this review, we discuss the consequence of Axl upregulation in cancers, provide evidence for its role in cancer progression and the development of drug resistance. We will also discuss the therapeutic potential of Axl in the treatment of cancer.

Automated summary

Axl is an oncogene that promotes cancer development and resistance to therapy, with inhibitors currently in clinical trials. Understanding the role of Axl in drug resistance can lead to improved cancer therapeutic strategies.